Purple Biotech Ltd PPBT
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -82.22%
- 1 year
- -87.55%
- Open
- 1.09
- Prev close
- 1.08
- Mkt cap
- 1.90M
- Vol
- 41.62K
- Avg vol
- 1.28M
- EPS
- -47.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.07
- High
- 1.17
- Forward P/E
- -1.69
- Beta
- 0.38
- Short ratio
- 0.43
- Inst. own
- 9.33%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.64
- 200-d avg
- 8.21
- 1y target
- 33.00
Key statistics
- Market cap
- 9.56M
- Enterprise value
- 695.00M
- Trailing P/E
- 0.00
- Forward P/E
- -1.69
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 27.21
- EPS (TTM)
- -8.10
- Beta
- 0.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -8.88M
- Total cash
- 7.39M
- Total debt
- 261.00K
- Return on equity
- -44.67%
- Shares outstanding
- 2.58M
- Short % of float
- 1.33%
- 50-day average
- 3.64
- 200-day average
- 8.21
Analyst view
Consensus: none
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.22.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 15, 2024 | Sep 1, 2024 | -1.20 | -1.37 | -0.17 | -14.17% |
| Aug 16, 2024 | Jun 1, 2024 | -2.60 | -1.60 | +1.00 | +38.46% |
| May 21, 2024 | Mar 1, 2024 | -3.00 | -3.00 | 0.00 | 0.00% |
| Mar 5, 2024 | Dec 1, 2023 | -3.40 | -6.40 | -3.00 | -88.24% |
| Nov 21, 2023 | Sep 1, 2023 | -4.40 | -4.20 | +0.20 | +4.55% |
| Aug 22, 2023 | Jun 1, 2023 | -5.00 | -4.60 | +0.40 | +8.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 20, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 19, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- purple-biotech.com
News
- Purple Biotech’s Abstract On IM1240, Lead Tri-Specific Antibody From CAPTN-3 Platform, Accepted For Oral Presentation At 38th EORTC-NCI-AACR Symposium
- Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Crude Oil Moves Higher; US Factory Orders Rise In July
- Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings
- Why Is Purple Biotech Stock Gaining Wednesday?
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Purple Biotech Issued Patent From U.S. Patent And Trademark Office For Its Application Covering Tri-Specific Antibody Constructs, Models
- New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
Your note
Sign in to keep a note on PPBT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 12.10% | 158,000 | 584.60K | Sep 29, 2024 |
| Morgan Stanley | 0.62% | 8,055 | 29.80K | Sep 29, 2024 |
| BNP Paribas Financial Markets | 0.28% | 3,675 | 13.60K | Sep 29, 2024 |
| Td Waterhouse Canada Inc. | 0.02% | 200 | 740 | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.02% | 254 | 939 | Sep 29, 2024 |
| Royal Bank of Canada | 0.01% | 107 | 395 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 633 | 2.34K | Oct 30, 2024 |